EMA explains when to use active controls in clinical trials
This article was originally published in SRA
The European Medicines Agency has issued a draft reflection paper explaining when drug companies should make use of active control in clinical trials. The scope of the paper is restricted to therapeutic areas where the use of a placebo is deemed ethical and one or more established medicines are available1,2.
You may also be interested in...
The UK’s deployment of COVID-19 vaccines has left vaccine manufacturers worried about emerging discussions on dosing strategies that may not be supported by authorized labeling or published clinical data.
Existing importers and manufacturers of certain medical devices can continue marketing their products for six months or until the Indian medtech regulator makes a final decision on their pending licensing applications.
Differences between how Australia and the EU define “central circulatory system” has resulted in different risk classification levels being assigned to some devices in the two jurisdictions.